3.81% -0.0475

Chromocell Therapeutics Corp (CHRO)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Chromocell Therapeutics Corp Borsa (CHRO) Ultime notizie

Chromocell Therapeutics Corp (CHRO)

Chromocell Therapeutics Corp Borsa (CHRO) Ultime notizie

Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga

Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks

Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.

Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com

Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia

Channel Therapeutics secures $325,000 promissory note - Investing.com India

New Biotech Stocks at Investorideas.com - Investorideas.com newswire

Wall Street-Heavily Traded - WDRB

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - StockTitan

Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan

Chromocell changes name to Channel Therapeutics, provides program updates - Nasdaq

Channel Therapeutics finalizes corporate restructuring - Investing.com

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times

Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan

Chromocell Therapeutics amends stock repurchase plan - TradingPedia

Chromocell Announces Amendment to Stock Repurchase Plan | CHRO Stock News - StockTitan

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire

Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra

Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance

CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online

IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online

Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC

Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView

Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan

Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech

Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine

Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan

CHRO Stock Price and Chart — AMEX:CHRO - TradingView

CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan

CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com

Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire

Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University

Stocks Telegraph - Stocks Telegraph

Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing

Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library

Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire

Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire

News from Central Jersey's pharma, biotech industries - Central New Jersey News

Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News

Simile a CHRO